NASDAQ:RETA

Reata Pharmaceuticals - RETA Stock Forecast, Price & News

$22.12

-1.94 (-8.06%)

(As of 09/23/2022 12:00 AM ET)

Add

Compare

Today's Range: $22.07
▼
$24.27
50-Day Range: $19.32
▼
$35.70
52-Week Range: $18.47
▼
$114.80

Volume: 634,923 shs
Average Volume: 1.05 million shs
Market Capitalization: $807.38 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $57.57

Reata Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 160.3% Upside
$57.57 Price Target
Short Interest: Healthy
14.57% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.75
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($8.37) to ($8.31) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.24 out of 5 stars

Medical Sector

352nd out of 1,075 stocks

Pharmaceutical Preparations Industry

152nd out of 532 stocks

3.3

Analyst's Opinion

Consensus Rating
Reata Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $57.57, Reata Pharmaceuticals has a forecasted upside of 160.3% from its current price of $22.12.
Amount of Analyst Coverage
Reata Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
14.57% of the float of Reata Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Reata Pharmaceuticals has a short interest ratio ("days to cover") of 5.6.
Change versus previous month
Short interest in Reata Pharmaceuticals has recently decreased by 11.25%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Reata Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Reata Pharmaceuticals does not have a long track record of dividend growth.

4.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Reata Pharmaceuticals has received a 78.64% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Reata Pharmaceuticals is -0.75.

0.0

News and Social Media Coverage

Search Interest
Only 2 people have searched for RETA on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Reata Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Reata Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
28.70% of the stock of Reata Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
76.00% of the stock of Reata Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Reata Pharmaceuticals are expected to grow in the coming year, from ($8.37) to ($8.31) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Reata Pharmaceuticals is -2.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Reata Pharmaceuticals is -2.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Reata Pharmaceuticals has a P/B Ratio of 4.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Reata Pharmaceuticals (NASDAQ:RETA) Stock

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.

Receive RETA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Reata Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RETA Stock News Headlines

September 13, 2022 | nasdaq.com

Investors in Reata Pharmaceuticals (NASDAQ:RETA) from a year ago are still down 76%, even after 13% gain this past week

September 12, 2022 | benzinga.com

Moore Kuehn, PLLC Encourages Investors of Reata Pharmaceuticals, Inc. to Contact Law Firm

September 10, 2022 | reuters.com

Reata Pharmaceuticals Inc

September 8, 2022 | benzinga.com

2RETA : Reata Pharmaceuticals Whale Trades Spotted

September 8, 2022 | finance.yahoo.com

Why Is Kodiak Sciences Inc. (KOD) Down 23.8% Since Last Earnings Report?

September 6, 2022 | finance.yahoo.com

Reata Pharmaceuticals Announces Participation in the Citi 17th Annual BioPharma Conference

August 14, 2022 | finance.yahoo.com

Time To Worry? Analysts Just Downgraded Their Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Outlook

August 9, 2022 | finance.yahoo.com

Reata Pharmaceuticals Announces Three Month Extension of the Review Period for New Drug Application for Omaveloxolone for the Treatment of Friedreich’s Ataxia

August 8, 2022 | seekingalpha.com

Reata Pharmaceuticals, Inc.'s (RETA) CEO Warren Huff on Q2 2022 Results - Earnings Call Transcript

August 8, 2022 | seekingalpha.com

Reata drops 33%, most since December; Goldman sees favorable risk reward profile

August 8, 2022 | finance.yahoo.com

Reata Pharmaceuticals, Inc. (RETA) Reports Q2 Loss, Lags Revenue Estimates

August 8, 2022 | finance.yahoo.com

Why Reata Pharma Shares Are Trading Lower After Q2 Earnings Update?

August 5, 2022 | benzinga.com

Reata Pharmaceuticals Earnings Preview

May 27, 2022 | seekingalpha.com

Reata extends gains as Citi welcomes regulatory win for lead asset

May 26, 2022 | finance.yahoo.com

FDA grants priority review to Reata's rare disease drug

May 6, 2022 | americanbankingnews.com

Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Given Consensus Recommendation of "Buy" by Analysts

May 2, 2022 | finance.yahoo.com

Reata Pharmaceuticals, Inc. to Report First Quarter 2022 Financial Results and to Provide an Update on Clinical Development Programs on May 10, 2022

April 8, 2022 | apnews.com

Moore Kuehn, PLLC Encourages Investors of ALEC, RETA, ASXM, and PTCT to Contact Law Firm

April 1, 2022 | finance.yahoo.com

Reata Stock Enjoys A Two-Day Climb — Why It Could Still Be Facing Everest

March 30, 2022 | finance.yahoo.com

Reata Pharmaceuticals, Inc. (RETA) Up 3.9% Since Last Earnings Report: Can It Continue?

March 30, 2022 | finance.yahoo.com

Reata Pharmaceuticals, Inc. (RETA) Stock Jumps 14.5%: Will It Continue to Soar?

March 28, 2022 | seekingalpha.com

Reata defended at Citi after FDA comments on ALS drug

March 18, 2022 | benzinga.com

Regulus Moving Closer To Potential $25 Million Milestone Payment For Novel Kidney Disease Treatment Licensed To Sanofi

February 28, 2022 | msn.com

Reata Pharmaceuticals Shares Rise 22% After Fourth Quarter Earnings

February 28, 2022 | nasdaq.com

Reata's (RETA) Q4 Earnings Miss Mark, Revenues Decline Y/Y

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive RETA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Reata Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RETA Company Calendar

Last Earnings: 8/08/2022
Today: 9/25/2022
Next Earnings (Estimated): 11/14/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:RETA
CUSIP: N/A
CIK: 1358762
Web: www.reatapharma.com
Phone: (972) 865-2219
Fax: N/A
Employees: 346
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $57.57
High Stock Price Forecast: $112.00
Low Stock Price Forecast: $27.00
Forecasted Upside/Downside: +160.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($8.37)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-297,390,000.00
Net Margins: -3,045.98%
Pretax Margin: -3,043.50%
Return on Equity: -190.87%
Return on Assets: -43.86%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 10.60
Quick Ratio: 10.60

Sales & Book Value

Annual Sales: $11.49 million
Price / Sales: 70.27
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.11 per share
Price / Book: 4.33

Miscellaneous

Outstanding Shares: 36,500,000
Free Float: 26,022,000
Market Cap: $807.38 million
Optionable: Optionable
Beta: 1.16

Key Executives

Mr. J. Warren Huff (Age 68)
Chairman & CEO
Comp: $642.4k

Mr. Manmeet Singh Soni (Age 44)
COO, CFO & Pres
Comp: $1.15M

Mr. Michael D. Wortley (Age 74)
Exec. VP & Chief Legal Officer
Comp: $563.22k

Dr. Colin J. Meyer M.D. (Age 43)
Exec. VP & Chief Innovation Officer
Comp: $742.5k

Ms. Dawn Carter Bir (Age 51)
Exec. VP & Chief Commercial Officer
Comp: $569.42k

Mr. Bhaskar Anand (Age 45)
VP & Chief Accounting Officer

Dr. W. Christian Wigley Ph.D.
Sr. VP & Chief Scientific Officer

Mr. Dakota Gallivan
VP & Chief Healthcare Compliance Officer

Mr. Steve Harman
Sr. VP & Chief HR Officer

Ms. Elaine Castellanos
Consultant

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

RETA Stock - Frequently Asked Questions

Should I buy or sell Reata Pharmaceuticals stock right now?: 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Reata Pharmaceuticals in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RETA shares.
View RETA analyst ratings or view top-rated stocks.
What is Reata Pharmaceuticals' stock price forecast for 2022?: 6 analysts have issued 12 month price targets for Reata Pharmaceuticals' stock. Their RETA share price forecasts range from $27.00 to $112.00. On average, they predict the company's stock price to reach $57.57 in the next twelve months. This suggests a possible upside of 160.3% from the stock's current price.
View analysts price targets for RETA or view top-rated stocks among Wall Street analysts.
How have RETA shares performed in 2022?: Reata Pharmaceuticals' stock was trading at $26.37 at the beginning of 2022. Since then, RETA shares have decreased by 16.1% and is now trading at $22.12.
View the best growth stocks for 2022 here.
When is Reata Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our RETA earnings forecast.
How were Reata Pharmaceuticals' earnings last quarter?: Reata Pharmaceuticals, Inc. (NASDAQ:RETA) issued its quarterly earnings results on Monday, August, 8th. The company reported ($2.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.90) by $0.12. The business earned $0.76 million during the quarter, compared to analyst estimates of $1.46 million. Reata Pharmaceuticals had a negative trailing twelve-month return on equity of 190.87% and a negative net margin of 3,045.98%. The firm's revenue for the quarter was down 65.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($2.00) earnings per share.
What is Warren Huff's approval rating as Reata Pharmaceuticals' CEO?: 10 employees have rated Reata Pharmaceuticals Chief Executive Officer Warren Huff on Glassdoor.com. Warren Huff has an approval rating of 92% among the company's employees. This puts Warren Huff in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Reata Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Reata Pharmaceuticals investors own include Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Synlogic (SYBX), NVIDIA (NVDA), Basic Energy Services (BAS), Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO) and Archrock (AROC).
When did Reata Pharmaceuticals IPO?: (RETA) raised $60 million in an IPO on Thursday, May 26th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO.
What is Reata Pharmaceuticals' stock symbol?: Reata Pharmaceuticals trades on the NASDAQ under the ticker symbol "RETA."
Who are Reata Pharmaceuticals' major shareholders?: Reata Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include State Street Corp (2.03%), Franklin Resources Inc. (1.74%), Deutsche Bank AG (1.73%), FMR LLC (1.45%), Price T Rowe Associates Inc. MD (1.37%) and Emerald Advisers LLC (0.79%). Insiders that own company stock include Colin John Meyer, Elaine Castellanos, James W Traweek Jr, James Warren Huff, Jason Douglas Wilson and Michael D Wortley.
View institutional ownership trends.
How do I buy shares of Reata Pharmaceuticals?: Shares of RETA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Reata Pharmaceuticals' stock price today?: One share of RETA stock can currently be purchased for approximately $22.12.
How much money does Reata Pharmaceuticals make?: Reata Pharmaceuticals (NASDAQ:RETA) has a market capitalization of $807.38 million and generates $11.49 million in revenue each year. The company earns $-297,390,000.00 in net income (profit) each year or ($8.37) on an earnings per share basis.
How many employees does Reata Pharmaceuticals have?: The company employs 346 workers across the globe.
How can I contact Reata Pharmaceuticals?: Reata Pharmaceuticals' mailing address is 5320 LEGACY DRIVE, PLANO TX, 75024. The official website for the company is www.reatapharma.com. The company can be reached via phone at (972) 865-2219 or via email at ir@reatapharma.com.

This page (NASDAQ:RETA) was last updated on 9/25/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial Subscription Here

Reata Pharmaceuticals - RETA Stock Forecast, Price & News

Reata Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month